^
Evidence Level:
Sensitive: C3 – Early Trials

[ROS1 rearrangement-Lung Non-Squamous Non-Small Cell Cancer-crizotinib]

Source:
Title:
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
Published date:
10/22/2021
Excerpt:
We enrolled 95 non-squamous NSCLC patients with known status of EGFR, ALK, ROS1, MET and RET genes and PD-L1 protein expression….In 32 patients with ALK or ROS1 genes rearrangements, 10 patients received crizotinib and 22 patients chemotherapy in the first-line of treatment. The median overall survival was 34 months (95% CI 9.5–34 months) in crizotinib treated patients and 6 months (95% CI 4–15.5 months) in patients who received chemotherapy (HR = 0.266, 95% CI 0.104–0.678, p = 0.0056)...
DOI:
https://doi.org/10.1038/s41598-021-00309-3
Evidence Level:
Sensitive: C3 – Early Trials

[ROS1 rearrangement-Lung Adenocarcinoma-crizotinib]

Title:
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Excerpt:
Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response....Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1....Crizotinib seems to be the current treatment of choice for ROS1-positive patients.
DOI:
10.1200/JCO.2014.58.3302